Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants

References

• Organization WH. Fact sheets – cancer 2022. [updated 2022 Feb 3; cited 2022 Nov 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• WHO. Global cancer observatory: cancer today. 2020. [cited 2022 Jul 25]. https://gco.iarc.fr/
   Google Scholar
• Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam-burden and control efforts: a narrative scoping review. Cancer Control. 2019;26(1):1073274819863802.
   Web of Science ®Google Scholar
• WHO. Cancer control: knowledge into action: WHO guide for effective programmes: module 3: early detection. Geneva: World Health Organization; 2007.
   Google Scholar
• Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965–1977.
   PubMed Web of Science ®Google Scholar
• Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. IAMA. 2018;320(7):674–686.
   PubMed Web of Science ®Google Scholar
• Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(4):279–296. doi:10.7326/M15-2886.
   PubMed Web of Science ®Google Scholar
• Force USPST. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962–970.
   PubMed Web of Science ®Google Scholar
• Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–1913. doi:10.1001/jama.2018.3710.
   PubMed Web of Science ®Google Scholar
• Ebell MH, Bentivegna M, Hulme C. Cancer-specific mortality, all-cause mortality, and overdiagnosis in lung cancer screening trials: a meta-analysis. Ann Fam Med. 2020;18(6):545–552. doi:10.1370/afm.2582.
   PubMed Web of Science ®Google Scholar
• Schoenborn NL, Sheehan OC, Roth DL, Cidav T, Huang J, Chung SE, et al. Association between receipt of cancer screening and all-cause mortality in older adults. JAMA Netw Open. 2021;4(6):e2112062. doi:10.1001/jamanetworkopen.2021.12062.
   PubMed Web of Science ®Google Scholar
• Stang A, Jöckel KH. The impact of cancer screening on all-cause mortality. Dtsch Arztebl Int. 2018;115(29-30):481–486.
   PubMed Web of Science ®Google Scholar
• Gini A, Jansen EEL, Zielonke N, Meester RGS, Senore C, Anttila A, et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. Eur J Cancer. 2020;127:224–235. doi:10.1016/j.ejca.2019.12.014.
   PubMed Web of Science ®Google Scholar
• Yan YY, Guo QR, Wang FH, Adhikari R, Zhu ZY, Zhang HY, et al. Cell-free DNA: hope and potential application in cancer. Front Cell Dev Biol. 2021;9:639233.
   PubMedGoogle Scholar
• Campos-Carrillo A, Weitzel JN, Sahoo P, Rockne R, Mokhnatkin JV, Murtaza M, et al. Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther. 2020;207:107458. doi:10.1016/j.pharmthera.2019.107458.
   PubMed Web of Science ®Google Scholar
• Tran LS, Nguyen QT, Nguyen CV, Tran VU, Nguyen TT, Le HT, et al. Ultra-deep massive parallel sequencing of plasma cell-free DNA enables large-scale profiling of driver mutations in vietnamese patients with advanced non-small cell lung cancer. Front Oncol. 2020;10:1351. doi:10.3389/fonc.2020.01351.
   PubMed Web of Science ®Google Scholar
• Nguyen Hoang V-A, Nguyen ST, Nguyen TV, Pham TH, Doan PL, Nguyen Thi NT, et al. Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer. Mol Oncol. 2023. doi:10.1002/1878-0261.13356.
   Google Scholar
• Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6(5):479–491. doi:10.1158/2159-8290.CD-15-1483.
   PubMed Web of Science ®Google Scholar
• Use of circulating tumor DNA for EarlyStage solid tumor drug development guidance for industry. 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-draft-guidance.
   Google Scholar
• Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–930. doi:10.1126/science.aar3247.
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Luong BA, Tran DH, Nguyen TH, Ngo QD, Le LGH, et al. Ultra-deep sequencing of plasma-circulating DNA for the detection of tumor-derived mutations in patients with nonmetastatic colorectal cancer. Cancer Invest. 2022;40(4):354–365. doi:10.1080/07357907.2021.2017951.
   PubMed Web of Science ®Google Scholar
• Croessmann S, Park BH. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Clin Adv Hematol Oncol. 2021;19(3):155–161.
   PubMed Web of Science ®Google Scholar
• Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928–1937. doi:10.1038/s41591-019-0652-7.
   PubMed Web of Science ®Google Scholar
• Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385–389. doi:10.1038/s41586-019-1272-6.
   PubMed Web of Science ®Google Scholar
• Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–759. doi:10.1016/j.annonc.2020.02.011.
   PubMed Web of Science ®Google Scholar
• Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167–1177. doi:10.1016/j.annonc.2021.05.806.
   PubMed Web of Science ®Google Scholar
• Hieu NT, Hai PT, Thuy PTT, Xuan JT, Chu NV, Huong TTT, et al. ESTABLISHMENT OF THE SPOT-MAS LISTENCE PROCESS TO Detect Many Types of Cancer FROM EARLY STAGE. VMJ [Internet]. April 27, 2022 [cited 2023 Feb 1]; 513(1). Available from: https://tapchiyhocvietnam.vn/index.php/vmj/article/view/2360.
   Google Scholar
• Nguyen HT, Khoa Huynh LA, Nguyen TV, Tran DH, Thu Tran TT, Khang Le ND, et al. Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer. Future Oncol. 2022;18(35):3895–3912. doi:10.2217/fon-2022-1041.
   PubMed Web of Science ®Google Scholar
• Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020;11(1):3475. doi:10.1038/s41467-020-17316-z.
   PubMed Web of Science ®Google Scholar
• Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(4):412–441. doi:10.6004/jnccn.2018.0020.
   PubMed Web of Science ®Google Scholar
• Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(11):1362–1389. doi:10.6004/jnccn.2018.0083.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(7):874–901. doi:10.6004/jnccn.2018.0061.
   PubMed Web of Science ®Google Scholar
• Benson AB, 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(3):370–398. doi:10.6004/jnccn.2017.0036.
   PubMed Web of Science ®Google Scholar
• Hummel EM, Hessas E, Müller S, Beiter T, Fisch M, Eibl A, et al. Cell-free DNA release under psychosocial and physical stress conditions. Transl Psychiatry. 2018;8(1):236. doi:10.1038/s41398-018-0264-x.
   PubMed Web of Science ®Google Scholar
• Yuwono NL, Warton K, Ford CE. The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma. Elife. 2021; 10:10. doi:10.7554/eLife.69679.
   Web of Science ®Google Scholar
• Alghofaili L, Almubarak H, Gassem K, Islam SS, Coskun S, Kaya N, Karakas B. Cell-free DNA levels of twins and sibling pairs indicate individuality and possible use as a personalized biomarker. PLoS One. 2019;14(10):e0223470. doi:10.1371/journal.pone.0223470.
   PubMed Web of Science ®Google Scholar
• Jylhävä J, Kotipelto T, Raitala A, Jylhä M, Hervonen A, Hurme M. Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the vitality 90+ study. Mech Ageing Dev. 2011;132(1-2):20–26. doi:10.1016/j.mad.2010.11.001.
   PubMed Web of Science ®Google Scholar
• Braunstein GD, Ofman JJ. Criteria for evaluating multi-cancer early detection tests. touchREVIEWS Oncol Haematol. 2021;17(1):3–6. doi:10.17925/OHR.2021.17.1.3.
   Google Scholar
• Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23. doi:10.1038/s41698-018-0066-x.
   PubMed Web of Science ®Google Scholar
• Liu MC. Transforming the landscape of early cancer detection using blood tests—commentary on current methodologies and future prospects. Br J Cancer. 2021;124(9):1475–1477. doi:10.1038/s41416-020-01223-7.
   PubMed Web of Science ®Google Scholar
• Nadauld LD, McDonnell CH, Beer TM, Liu MC, Klein EA, Hudnut A, et al. The PATHFINDER study: assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers. 2021; 13(14):3501. doi:10.3390/cancers13143501.
   PubMed Web of Science ®Google Scholar
• Abstract 903O ‘A prospective study of a multi-cancer early detection blood test’ was presented by Deb Schrag during the proffered paper session “Basic science and translational research”: Annals of Oncology. 2022. [cited 2022 Oct]. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-congress/a-prospective-study-of-a-multi-cancer-early-detection-blood-test.
   Google Scholar
• Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499):eabb9601. doi:10.1126/science.abb9601.
   PubMed Web of Science ®Google Scholar
• Meng Z, Ren Q, Zhong G, Li S, Chen Y, Wu W, et al. Noninvasive detection of hepatocellular carcinoma with circulating tumor DNA features and α-fetoprotein. J Mol Diagn. 2021;23(9):1174–1184.
   PubMed Web of Science ®Google Scholar
• Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921.
   PubMed Web of Science ®Google Scholar